Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review
View abstract on PubMed
Summary
This summary is machine-generated.Predicting hepatocellular carcinoma (HCC) recurrence after liver resection is crucial. While new biomarkers show promise, inflammation markers are more accessible and reproducible for clinical use.
Area Of Science
- Hepatobiliary surgery
- Oncology
- Biomarker discovery
Background
- Hepatocellular carcinoma (HCC) liver resection offers curative potential but faces high recurrence rates (up to 70%).
- Traditional predictors include pathological factors and alpha-fetoprotein levels.
- Emerging biomarkers like liquid biopsies and gene signatures show prognostic value but face accessibility and reproducibility challenges.
Purpose Of The Study
- To review and assess novel biomarkers for predicting recurrence and survival after HCC resection.
- To evaluate the clinical utility and reproducibility of various prognostic markers.
Main Methods
- Literature review of studies on biomarkers for HCC recurrence and survival post-resection.
- Analysis of traditional, liquid biopsy, gene expression, and inflammation-based markers.
- Assessment of marker accessibility, reproducibility, and clinical applicability.
Main Results
- Liquid biopsy and gene signatures show prognostic potential but have limitations in cost and heterogeneity.
- Inflammation markers (e.g., prognostic nutritional index, blood cell ratios) appear more reproducible and affordable.
- Existing markers are insufficient for optimal treatment selection.
Conclusions
- Validation of reliable and widely reproducible predictive markers for HCC recurrence and survival is essential.
- Accessible inflammation markers offer a promising avenue for clinical application.
- Further evidence, particularly from Western cohorts, is needed to corroborate findings.

